lisocabtagene maraleucel,,Cyclophosphamide,Fludarabine
BMS
['lisocabtagene', 'mantle,(-dismantle)', 'breyanzi', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'lymphoma', 'follicular', 'bristol', '$bmy']
bristol myers squibb s breyanzi (lisocabtagene maraleucel) delivers deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma in transcend clinical trials presented at icml 2023 - health stocks hub $bmy 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2